Arix Bioscience PLC (LON:ARIX) has noted poster presentations from two of its portfolio companies at the Annual Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program that starts today.
Harpoon Therapeutics Inc (NASDAQ:HARP), presented interim data from the ongoing dose-escalation portion of a Phase 1 trial for HPN424 in patients with metastatic castration-resistant prostate cancer (mCRPC).
Autolus Therapeutics PLC ( (NASDAQ: AUTL), announced new dataRead More – Source
[contf]
[contfnew]
Proactiveinvestors
[contfnewc]
[contfnewc]
